SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akers Biosciences, Inc. (AKER)

NEW YORK, June 13, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/aker.

The investigation concerns whether Akers and certain of its officers and/or directors have violated federal securities laws.

On May 21, 2018, Akers revealed that it would delay filing its Form 10-Q with the SEC for the quarter ended March 31, 2018 and that will continue reviewing the "characterization of certain revenue recognition items . . . now includes certain transactions in previous quarters." Following this news, Akers stock dropped $0.058 per share or over 8% to close at $0.599 per share on May 22, 2018.

On May 29, 2018, Akers announced that "Raymond F. Akers Jr., Ph.D. has resigned as a director of the Company with immediate effect." Following this news, Akers stock dropped $0.198 per share or over 33% to close at $0.391 on May 29, 2018.

Then on June 1, 2018, Akers filed a letter with the SEC from Raymond Akers that said that Dr. Akers "resigned from the Board of Directors due to significant differences regarding the policies and practices of the Board of Directors, accounting and business practices of Management, and new Counsel."

If you are aware of any facts relating to this investigation, or purchased Akers shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/aker. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-akers-biosciences-inc-aker-300665795.html

SOURCE Bronstein, Gewirtz & Grossman, LLC